Type 1 diabetes results from autoimmune-mediated destruction of β cells. The tyrosine kinase inhibitor imatinib might affect relevant immunological and metabolic pathways, and preclinical studies show that it reverses and prevents diabetes. Our aim was to evaluate the safety and efficacy of imatinib in preserving β-cell function in patients with recent-onset type 1 diabetes.
Alfonso Bellia, Aikaterini Andreadi, Luca Giudice, Sofia De Taddeo, Alessio Maiorino, Ilenia D'Ippolito, Federica Maria Giorgino, Valeria Ruotolo, Maria Romano, Andrea Magrini, Nicola Di Daniele, Paola Rogliani, Davide Lauro
Diabetes Care 2021 July 12
June 25, 2021
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown.
Diabetes Care 2021 January 4
Objective: To compare efficacy and safety of dulaglutide at doses of 3.0 and 4.5 mg versus 1.5 mg in patients with type 2 diabetes inadequately controlled with metformin.
Endocrinología, Diabetes y Nutrición
páginas 545-552 (Octubre 2020)
Mercè Codina, Rosa Corcoy, María M. Goya, en representación del GEDE Consenso del Grupo Español de Diabetes y Embarazo (GEDE)
DOCUMENTO DE CONSENSO
August 20, 2020 - N Engl J Med 2020; 383:721-732
Some studies have suggested that in people with type 2 diabetes, Roux-en-Y gastric bypass has therapeutic effects on metabolic function that are independent of weight loss.